U.S. FDA to reconsider decision barring compounded versions of Lilly weight loss drug

U.S. FDA to reconsider decision barring compounded versions of Lilly weight loss drug


Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Cristina Arias | Cover | Getty Images

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly’s blockbuster weight loss and diabetes drugs.

The agency said in a court filing it would now allow compounding pharmacies and facilities to keep providing the drugs while it reviews whether there is a shortage of their active ingredient. The compounding versions of the drugs are cheaper for patients than the brand-name versions.

The decision was in response to a lawsuit brought on Monday by the Outsourcing Facilities Association, a compounding industry group. After the FDA’s decision on Friday to reconsider, U.S. District Judge Mark Pittman in Fort Worth, Texas, put the lawsuit on hold.

The Sept. 30 decision by the FDA endangered the ability of compounders to sell versions of Lilly’s weight loss drug Zepbound and diabetes drug Mounjaro. The FDA decision removed their active ingredient, tirzepatide, from its list of drugs experiencing shortages.

That would have cut off access for many patients to the compounded versions they relied on during the shortage, which are cheaper than the brand name drugs. Insurers generally cover drugs like tirzepatide for diabetes, but many do not cover them for weight loss.

CNBC Investigates: Ozempic underworld

Outsourcing Facilities Association Chairman Lee Rosebush said in a statement the group was “greatly relieved, for our members and the many patients that they serve, that the FDA has agreed to reconsider its decision.”

Federal regulations allow compounded versions of an FDA-approved drug to be sold to meet demand if the drug is in short supply. If there is no shortage of a drug, compounded versions of it cannot be made regularly or in large amounts.

The Outsourcing Facilities Association claimed in its lawsuit the FDA removed tirzepatide from its shortage list even though it remained in short supply.

Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed lawsuits against sellers falsely claiming to sell FDA-approved versions of the drug.

The active ingredient in Novo Nordisk’s drugs, semaglutide, remains on the FDA’s shortage list.

Don’t miss these insights from CNBC PRO



Source

Japan’s Takaichi picks ex-premier Aso as party vice president
World

Japan’s Takaichi picks ex-premier Aso as party vice president

Taro Aso, Japan’s former deputy prime minister and finance minister, delivered a speech during an ordinary session at the lower house of the parliament in Tokyo, Japan, on Monday, Jan. 20, 2020. Photographer: Kiyoshi Ota/Bloomberg via Getty Images Bloomberg | Bloomberg | Getty Images Sanae Takaichi, who is expected to become Japan’s next prime minister, chose former premier and party heavyweight Taro Aso on Tuesday […]

Read More
CNBC Daily Open: The AI industry’s ‘happy few’ 
World

CNBC Daily Open: The AI industry’s ‘happy few’ 

Companies touting their artificial intelligence products dominated the Promenade, the main road in Davos. In past years at the World Economic Forum annual meeting, cryptocurrency firms were the most prominent down the Promenade. But AI fever has taken over in 2024. Arjun Kharpal | CNBC “We few, we happy few, we band of brothers.” The […]

Read More
Staffing issues cause delays at U.S. airports as shutdown persists
World

Staffing issues cause delays at U.S. airports as shutdown persists

Sean Duffy, U.S. secretary of transportation, during a news conference in Terminal A at Newark Liberty International Airport (EWR) in Newark, New Jersey, US, on Monday, Oct. 6, 2025. Michael Nagle | Bloomberg | Getty Images The Federal Aviation Administration said staffing issues were causing delays at several airports, including Newark and Denver, on Monday, […]

Read More